BioMarin Pharmaceutical (BMRN) reported Q1 non-GAAP earnings late Thursday of $1.13 per diluted share, up from $0.71 a year earlier.
Analysts polled by FactSet expected $0.95.
Revenue in the three months ended March 31 rose to $745.1 million from $648.8 million a year earlier.
Analysts surveyed by FactSet expected $738.7 million.
The company reiterated 2025 non-GAAP diluted EPS guidance of $4.20 to $4.40, on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet expect EPS of $4.30 on revenue of $3.14 billion.
Shares of BioMarin rose 1.1% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。